IP Library Granted Patent US 12,508,240
Granted Patent B2
US 12,508,240 · App. 17/784,846 · Granted Dec 30, 2025

Liquid composition comprising ibuprofen and phenylephrine

Inventors: Marta Vicario De La Torre (Madrid, ES); Nuria Sanz Menéndez (Madrid, ES); José Ángel Sánchez García (Madrid, ES); José Carlos Iglesias Sánchez (Madrid, ES); Luis Sante Serna (Madrid, ES)
Assignee: FARMALÍDER, S.A.
A61K31/192A61K9/0053A61K9/10A61K31/137A61K47/10A61K47/26A61K47/36A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,240
App. No.
17/784,846
Granted
Dec 30, 2025
Kind
B2
Abstract

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

Claims (31)

1 . A liquid pharmaceutical composition for oral administration in the form of suspension which comprises:

a) Ibuprofen in an amount comprised between 2% w/v and 10% w/v;

b) phenylephrine or a pharmaceutically acceptable salt thereof, in an amount comprised between 0.005% w/v and 2% w/v, expressed as equivalent amount of phenylephrine hydrochloride;

c) hypromellose, in an amount comprised between 0.1% w/v and 5% w/v;

d) xanthan gum, in an amount comprised between 0.05% w/v and 4% w/v;

e) liquid maltitol;

f) glycerine; and

g) water.

2 . The composition according to claim 1 , wherein phenylephrine is in the form of a salt selected from phenylephrine hydrochloride, phenylephrine hydrobromide and phenylephrine bitartrate.

3 . The composition according to claim 2 , wherein phenylephrine is in the form of phenylephrine hydrochloride.

4 . The composition according to claim 1 , wherein the amount of ibuprofen is comprised between 3% w/v and 5% w/v.

5 . The composition according to claim 1 , wherein the amount of phenylephrine or a pharmaceutically acceptable salt thereof is comprised between 0.08% w/v and 0.2% w/v, expressed as equivalent amount of phenylephrine hydrochloride.

6 . The composition according to claim 1 , wherein the amount of hypromellose is comprised between 0.2% w/v and 2% w/v.

7 . The composition according to claim 1 , wherein the amount of xanthan gum is comprised between 0.1% w/v and 2% w/v.

8 . The composition according to claim 1 , wherein the amount of liquid maltitol is comprised between 30% w/v and 70% w/v.

9 . The composition according to claim 1 , wherein the amount of glycerine is comprised between 5% w/v and 15% w/v.

10 . The composition according to claim 1 , wherein said composition comprises a pH adjusting agent to adjust the pH of the composition to a value comprised between 2 and 6.

11 . The composition according to claim 1 , wherein said composition comprises a preservative.

12 . The composition according to claim 1 , wherein said composition comprises a sweetening agent selected from acesulfame potassium, alitame, neohesperidin dihydrochalcone, neotame, saccharin, saccharin sodium, sucralose, thaumatin, and mixtures thereof.

13 . The composition according to claim 1 , wherein said composition comprises sodium chloride.

14 . A process for preparing the composition of claim 1 , wherein said process comprises the following steps:

(i) mixing hypromellose, xanthan gum and one part of the liquid maltitol with one part of total water to obtain a homogeneous mixture;

(ii) separately mixing ibuprofen, phenylephrine or a pharmaceutically acceptable salt thereof, glycerine and the rest of liquid maltitol with another part of total water, to obtain a homogeneous mixture;

(iii) adding the mixture of step (ii) to the mixture of step (i);

(iv) adding the rest of water.

15 . A method of treating symptoms of flu and common cold, comprising administering a therapeutically effective dose of the composition according to claim 1 to a patient in need thereof.

16 . The composition according to claim 1 , wherein the amount of hypromellose is comprised between 0.4% w/v and 0.6% w/v.

17 . The composition according to claim 1 , wherein the amount of xanthan gum is comprised between 0.3% w/v and 0.6% w/v.

18 . The composition according to claim 1 , wherein the amount of liquid maltitol is comprised between 45% w/v and 55% w/v.

19 . The composition according to claim 1 , wherein the amount of glycerine is comprised between 9% w/v and 11% w/v.

20 . The composition according to claim 1 , wherein said composition comprises a mixture of saccharin sodium and thaumatin as sweetening agent.

Assignments (2)
MERGER Recorded Nov 28, 2025
From: NUTRA ESSENTIAL OTC, S.L.U.
To: FARMALÍDER, S.A.
Reel/Frame 073792/0574 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 60182 FRAME: 764. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Nov 11, 2025
From: VICARIO DE LA TORRE, MARTA; SANZ MENÉNDEZ, NURIA; SÁNCHEZ GARCÍA, JOSÉ ÁNGEL; IGLESIAS SÁNCHEZ, JOSÉ CARLOS; SANTE SERNA, LUIS
To: MMC INTERNATIONAL HEALTH HOLDING, S.L.U.
Reel/Frame 073834/0551 →
Priority Claims (1)
EP 19383192 · Dec 23, 2019 · regional
Continuity (1)
Related Publication 20230012144A1 · Jan 12, 2023
References Cited (21)
US 20080014274A1 · Bubnis · 2008 [cited by examiner]
US 20110124730A1 · Atkinson · 2011 [cited by examiner]
US 20160045465A1 · Lomaga · 2016 [cited by applicant]
AU 2015222882A1 · 2016 [cited by applicant]
CN 101431991A · 2009 [cited by applicant]
CN 101939411A · 2011 [cited by applicant]
EP 1059084 · 2012 [cited by applicant]
GB 971700 · 1964 [cited by applicant]
WO WO9824414 · 1998 [cited by applicant]
WO WO2005115353 · 2005 [cited by applicant]
WO WO2006022996 · 2006 [cited by applicant]
WO WO2007098128 · 2007 [cited by applicant]
WO WO2008008364 · 2008 [cited by applicant]
WO WO2008008944 · 2008 [cited by applicant]
WO WO2008064192 · 2008 [cited by applicant]
Bhushan et al., Resolution of enantiomers of ibuprofen by liquid chromatography: a review. Biomed Chromatogr. Nov.-Dec. 1998;12(6):309-16. [cited by applicant]
Asare-Addo et al., Aqueous and hydro-alcoholic media effects on polyols, Colloids and Surfaces B: Biointerfaces, vol. 111, Nov. 1, 2013, pp. 24-29. [cited by applicant]
Bochkov et al., Effect of high molecular weight excipients on optimization of pharmacokinetic properties of drugs, Pharmacokinetics and Pharmacodynamics, 2016; (1):3-11. [cited by applicant]
Kovalsky, Increasing the bioavailability of rutin from solid dosage forms by the method of solid dispersions (tesis de doctorado), Moscow, 2015, disponible desde Aug. 19, 2015, p. 24. [cited by applicant]
Krstonosic et al., Influence of xanthan gum on oil-in-water emulsion characteristics stabilized by OSA starch, Food Hydrocolloids, vol. 45, Mar. 2015, pp. 9-17. [cited by applicant]
Verhoeven et al., Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: in vitro and in vivo evaluation, European Journal of Pharmaceutics and Biopharmaceu… [cited by applicant]